education_AdobeStock_©-Robert-Kneschke_251314673_2000px_191205

CATCOVID (CCR1 antagonist treatment in patients hospitalized with COVID-19)

CATCOVID

Clinical manifestations of coronavirus disease 2019 (COVID-19) range from no or mild symptoms to critical disease courses with acute respiratory failure. The overall goal of our study is to evaluate the effects of the CCR 1 inhibitor BAY 86-5277 in patients hospitalized for COVID-19 with need for additional respiratory support. Together with our partners (Bayer AG, Charité - Universitätsmedizin Berlin, Universitätsklinikum Leipzig, Universitätsklinikum Würzburg, BG Klinikum Unfallkrankenhaus Berlin) we´ve started a clinical trial and enrolled the first patient December 22nd 2021, in Leipzig.

DRKS-ID of this study:  DRKS00024465

Scientific Background: Data from single-cell studies provided a mechanistic understanding on how the immune response in the airways is orchestrated in COVID-19 patients. We observed a significant induction of CCL2, CCL3, and CCL4 expression in macrophages together with an increased expression of the corresponding chemokine receptor 1 (CCR1) in different immune cells in patients with critical COVID-19 (Chua et al. 2020, Nat Biotechnol, Trump et al. 2020, Nat Biotechnol). Because binding of the chemokines to their receptor can induce immune cell recruitment into the lung parenchyma with subsequent differentiation into inflammatory phenotypes, CCR1 might represent a promising target in critical COVID-19.

Details will follow.

Read more press release: Federal Ministry of Education and Research

Read more BIH: press release 1

                                     press release 2

                                               

BMBF_gefördert vom_en

Latest News

Übergabe der Gaia-X Zuwendungsbescheide - 24. Februar 2022

  Das Bundesministerium für Wirtschaft und Klimaschutz hat am 24. Februar 2022 die Zuwendungsbescheide für die 11 geförderten Projekte im Gaia-X Förderwettbewerb „Innovative und praxisnahe

Press conference, Berlin 28.01.2022

Roland Eils: „Insgesamt kann man mit Fug und Recht behaupten, dass wir mit Hilfe der MII einen bedeutenden, wenn nicht sogar den wichtigsten Schub zur Digitalisierung des Gesundheitsbereichs nach

Charités paper of the month

Children can also be infected with the novel coronavirus SARS-CoV-2, but have a substantially lower risk for developing severe COVID-19 disease compared to adults. A team of scientists from the

ELIXIR Reproducible Research Workshop

Reproducibility is a cornerstone of good scientific practice. This workshop brings together the biggest names in bioinformatics workflow management for a 3 day practical workshop. For more